Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
SOS1 DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/223034
Kind Code:
A1
Abstract:
An SOS1 degradation agent and a preparation method therefor and an application thereof. Specifically, disclosed is a compound of formula I: S-L-E(I), wherein L is a linking chain, which links S and E by means of covalent bonds; E is a small molecule ligand of an E3 ubiquitin ligase complex; and S is the structure shown in S7. The compound of formula I is capable of degrading and/or inhibiting SOS1 protein in cells, and can be used for treating and/or preventing related diseases or conditions mediated by SOS1 or caused by interaction of SOS1 and Ras, or SOS1 and Rac.

More Like This:
JP6496301Quinazoline and azakinazoline as dual inhibitors of the RAS / RAF / MEK / ERK pathway and the PI3K / AKT / PTEN / MTOR pathway
JP2001522802INDUSTRIAL APPLICABILITY The use of a quinazoline derivative as a tyrosine kinase inhibitor for treating colorectal polyps.
WO/2004/031161NEUROLOGICALLY-ACTIVE COMPOUNDS
Inventors:
YE ZHENGQING (CN)
FENG YAN (CN)
LI SHIQIANG (CN)
DING CHENLI (CN)
WANG QIAO (CN)
WEI HONG (CN)
XIE SHUCHEN (CN)
Application Number:
PCT/CN2022/088561
Publication Date:
October 27, 2022
Filing Date:
April 22, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SHANGHAI LEADINGTAC PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D239/94; A61K31/517; A61P35/00; C07D409/14
Domestic Patent References:
WO2022061348A12022-03-24
WO2018172250A12018-09-27
WO2019140380A12019-07-18
WO2018115380A12018-06-28
Foreign References:
CN112218859A2021-01-12
Other References:
ZHOU, CHUAN ET AL.: "Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations.", J. MED. CHEM., vol. 65, 1 March 2022 (2022-03-01), pages 3923 - 3942, XP055978386, DOI: 10.1021/acs.jmedchem.1c01774
HILLIG, R. C. ET AL.: "Discovery of Potent SOS1 Inhibitors that Block RAS Activation Via Disruption of the RAS–SOS1 Interaction.", PNAS, vol. 116, no. 7, 12 February 2019 (2019-02-12), pages 2551 - 2560, XP055841142, DOI: 10.1073/pnas.1812963116
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Next Patent: MESSAGE PUSHING METHOD AND APPARATUS, AND DEVICE AND READABLE MEDIUM